MAGI2 and Miyoshi myopathy: Here, combining analysis of THZ1-responsive transcripts, MM-SE genes and clinical-relevant markers, we identified one novel SE-controlled oncogene, MAGI2. Previously, MAGI2 was reported to interact with core proteins of multiple pathways, such as transforming growth factor-β signalling and Wnt/β-catenin signaling24.